CompletedPhase 1NCT04672824
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults
Studying Coccidioidomycosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Oxford
- Principal Investigator
- Pontiano Kaleebu, PhDMRC/UVRI and LSHTM Uganda Research Unit
- Intervention
- ChAdOx1 RVF(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2022 – 2022
Study locations (1)
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
Collaborators
MRC/UVRI and LSHTM Uganda Research Unit
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04672824 on ClinicalTrials.govOther trials for Coccidioidomycosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06799234Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)University of Oxford
- ACTIVE NOT RECRUITINGPHASE1NCT06925919Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011IDBiologics, Inc.
- ACTIVE NOT RECRUITINGNANCT06913803To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum FemalesSuperior University
- RECRUITINGPHASE2NCT03609398Phase 2 Safety and Immunogenicity Study of Rift Valley Fever VaccineU.S. Army Medical Research and Development Command
- RECRUITINGNCT02190266Pathogenesis and Genetics of Disseminated or Refractory CoccidioidomycosisNational Institute of Allergy and Infectious Diseases (NIAID)